Business
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
MONTPELLIER, France, September 17, 2025--Regulatory News: Medincell (Paris:MEDCL):
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/6b925c5afe8553a99d98923b5c379806"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F2.8mby0wKXBmRcOyTUT.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6b925c5afe8553a99d98923b5c379806","width":960,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/f2RSjXdvchdjButLOCpUdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6b925c5afe8553a99d98923b5c379806","width":640,"height":107},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LQGeRMlziSAKuXPER.On2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6b925c5afe8553a99d98923b5c379806","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, September 17, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL):","length":24,"tagName":"p"},{"type":"text","content":"Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California","length":172,"tagName":"p"},{"type":"text","content":"Teva will host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 am ET to discuss these data","length":127,"tagName":"p"},{"type":"text","content":"To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations","length":138,"tagName":"p"},{"type":"text","content":"Olanzapine LAI (mdc-TJK / TEV-‘749) is an investigational, once-monthly, subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the second drug within the Teva partnership – after UZEDY® approved by the FDA in April 2023 – that uses Medincell’s co-polymer technology (licensed to Teva under the name SteadyTeq™) to generate a controlled steady release of drug throughout the dosing interval. Teva is currently preparing for regulatory submission and launch of Olanzapine LAI with NDA submission anticipated in Q4 20...